Clinical trial NCT02834169: French National Registry of Rare Peritoneal Surface Malignancies
Official title: French National Registry of Rare Peritoneal Surface Malignancies (RENAPE Registry)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Rare Peritoneal Surface Malignancies
Pseudomyxoma Peritonei
Peritoneal Mesothelioma
Desmoplastic Small Round Cell Tumor
Psammocarcinoma
Primary Peritoneal Serous Carcinoma
Diffuse Peritoneal Leiomyomatosis
Appendiceal Mucinous Neoplasms
Keywords: Rare peritoneal surface malignancies
pseudomyxoma peritonei
peritoneal mesothelioma
desmoplastic small round cell tumor
psammocarcinoma
primary peritoneal serous carcinoma
diffuse peritoneal leiomyomatosis
appendiceal mucinous neoplasms
registry
population-based database
Lead sponsor: Hospices Civils de Lyon
Sponsor class: OTHER
First posted: 2016-07-15
Enrollment: 2171
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Prospectively or retrospectively diagnosed patients with rare peritoneal surface malignancies.

Brief summary: Despite advances in the management of and changes in clinical practice, little is known about the epidemiology, patterns of care and outcomes of rare peritoneal surface malignancies patients in France.

In order to better understand the characteristics of rare peritoneal surface malignancies and to evaluate treatment strategies, the RENAPE registry aims at the collection of data from patients presenting with a rare peritoneal surface malignancy in France. Data will be entered prospectively in a specifically designed and secured web database.

All RENAPE's centres and physicians are invited to register patients with a rare peritoneal surface malignancy diagnosis and to participate to the registry. Data will be evaluated within regular time frames, focusing on types of rare peritoneal surface malignancies, treatment modalities and patient outcomes (e.g. survival, recurrence), thereby contributing to the better understanding of these rare cancers.


Eligibility criteria: Inclusion Criteria:

* Patients are eligible if they have a histologically proven rare peritoneal surface malignancy.

Exclusion Criteria:

* Histological diagnostic of peritoneal surface malignancy not confirmed
* Expected clinical follow up data not available

Primary outcomes:
measure: Incidence of rare peritoneal surface malignancies
timeFrame: year 5
Secondary outcomes:
measure: Impact of specific treatment strategies
timeFrame: year 5
Other outcomes:
Locations:
city: Angers
country: France
facility: Institut de Cancérologie de l'Ouest - Paul Papin
city: Besancon
country: France
facility: CHU Jean Minjoz
city: Bordeaux
country: France
facility: Institut Bergonié
city: Caen
country: France
facility: Centre François Baclesse
city: Clermont-ferrand
country: France
facility: CHU Estaing
city: Clermont-ferrand
country: France
facility: Centre Jean Perrin
city: Colombes
country: France
facility: AP-HP Louis MOURIER
city: Dijon
country: France
facility: CHU Bocage
city: La Tronche
country: France
facility: CHU A. Michallon
city: Lille
country: France
facility: Centre Oscar Lambret
city: Lille
country: France
facility: CHRU Claude Huriez
city: Lyon
country: France
facility: Centre Léon Bérard
city: Marseille
country: France
facility: Institut Paoli Calmettes
city: Marseille
country: France
facility: Hôpital La Timône
city: Montpellier
country: France
facility: Institut du Cancer Montpellier
city: Nantes
country: France
facility: CHU Nantes Hôtel-Dieu
city: Nice
country: France
facility: CHU L'Archet II
city: Paris Cedex 10
country: France
facility: AP-HP Lariboisière
city: Paris Cedex 15
country: France
facility: AP-HP Hôpîtal Europeen Georges Pompidou
city: Paris
country: France
facility: Institut Curie
city: Paris
country: France
facility: AP-HP St Antoine
city: Paris
country: France
facility: AP-HP La Pitié-Salpêtrière
city: Pierre-benite
country: France
facility: Hospices Civils de Lyon - Centre Hospitalier Lyon Sud - Service de Chirurgie Générale et Digestive - 165 chemin du grand Revoyet,
city: Poitiers
country: France
facility: CHU Poitiers
city: Reims
country: France
facility: Hôpital Robert Debré
city: Rouen
country: France
facility: CHU Charles Nicolle
city: Saint Herblain
country: France
facility: Institut Cancérologie de l'Ouest - René Gauducheau
city: St Etienne
country: France
facility: CHU Nord
city: Strasbourg
country: France
facility: CHRU Hautepierre
city: Toulouse
country: France
facility: Institut Claudius Regaud
city: Toulouse
country: France
facility: Hôpital Purpan
city: Vandoeuvre-les-nancy
country: France
facility: Institut de Cancérologie de Lorraine
city: Villejuif
country: France
facility: Institut Gustave Roussy
Study officials:
affiliation: Hospices Civils de Lyon - Centre Hospitalier Lyon Sud - Service de Chirurgie Générale et Digestive - 165 chemin du grand Revoyet, PIERRE-BENITE, FRANCE, 69495
name: François-Noël GILLY, Prof
role: PRINCIPAL_INVESTIGATOR
References:
citation: Villeneuve L, Passot G, Glehen O, Isaac S, Bibeau F, Rousset P, Gilly FN; RENAPE Network. The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. Orphanet J Rare Dis. 2017 Feb 17;12(1):37. doi: 10.1186/s13023-017-0571-y.